This issue raised caution regarding the use of romosozumab, a novel monoclonal antibody for the treatment of osteoporosis that binds and inhibits sclerostin, due to a hypothetical worsening of RA and other autoimmune diseases that involve TNF-dependent inflammation. Here, SOST is linked to rheumatoid arthritis.